key: cord-1035695-v4yus0z4 authors: Schellenberg, J. J.; Ormond, M. A.; Keynan, Y. title: Is the glass half full? Extraction-free RT-LAMP to detect SARS-CoV-2 is less sensitive but highly specific compared to standard RT-PCR in 101 samples date: 2020-12-08 journal: nan DOI: 10.1101/2020.12.07.20239558 sha: 88c414ff509e0a2b83c3c90b232da9900fb894dc doc_id: 1035695 cord_uid: v4yus0z4 The current scale of public and private testing cannot be expected to meet the emerging need for higher levels of community-level and repeated screening of asymptomatic Canadians for SARS-CoV-2. Rapid point-of-care techniques are increasingly being deployed to fill the gap in screening levels required to identify undiagnosed individuals with high viral loads. However, rapid, point-of-care tests often have lower sensitivity in practice. Reverse transcription loop-mediated isothermal amplification (RT-LAMP) for SARS-CoV-2 has proven sensitive and specific and provides visual results in minutes. Using a commercially available kit for RT-LAMP and primer set targetting nucleocapsid (N) gene, we tested a blinded set of 101 archived nasopharyngeal (NP) swab samples with known RT-PCR results. RT-LAMP reactions were incubated at 65{degrees}C for 30 minutes, using heat-inactivated nasopharyngeal swab sample in viral transport medium, diluted tenfold in water, as input. RT-LAMP agreed with all RT-PCR defined negatives (N=51), and all positives with Ct less than 20 (N=24), 65% of positives with Ct between 20-30 (N=17), and no positives with Ct greater than 30 (N=9). RT-LAMP requires fewer and different core components, so may not compete directly with the mainline testing workflow, preserving precious central laboratory resources and gold standard tests for those with the greatest need. Careful messaging must be provided when using less-sensitive tests, so that people are not falsely reassured by negative results "glass half empty" - in exchange for reliable detection of those with high levels of virus within an hour, using <$10 worth of chemicals - "glass half full". In an unprecedented scientific feat, nucleic acid amplification tests (NAAT) for SARS-CoV-2 were published 21 days after the Chinese communicable disease control team arrived in Wuhan on 31 December 2019 1 , based on complete genome sequences published 10 days earlier 2 . Hundreds of molecular diagnostic tests for SARS-CoV-2 have been introduced since then 3-5 . The main diagnostic targets rely on specific host antibodies, viral proteins and viral RNA, each with its own specific benefits and limitations in accurately detecting the SARS-CoV-2 infectious period to prevent its spread. The best, most sensitive examples of tests to detect each target require high levels of laboratory expertise and specialized facilities that massively increase expense and turnaround time, especially when challenged with recent, unprecedented testing volumes. In addition, high throughput platforms used in laboratories have been diverted to testing for SARS-CoV-2 at the expense of other infectious disease testing 6 . Advice on whether to test people "without symptoms" (which represents a range of presymptomatic, peri-symptomatic, sub-symptomatic and truly asymptomatic phenotypes) wavers as much over time as actual demand for testing by people "without symptoms" 7, 8 . Constant demand on the testing sites has led to "covid fatigue", exhaustion of resources and delays in testing for sexually transmitted infections that have not diminished during the current pandemic. The arguments for not testing individuals "without symptoms", since only a small percentage test positive, make sense when investing the most precise, most expensive and most time-consuming test available, for such a small return, considering the cost for human and reagent resources. In a parallel system for screening people "without symptoms" (for example, the Iceland model 9 ), that is much cheaper and faster per person, doesn't occupy the commercial platforms used in diagnostic laboratories, and with a 50-75% sensitivity might start looking like "a glass half full". All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint Point-of-care assays that can rapidly indicate infection outside the laboratory have been approved for use in many jurisdictions. These include rapid antibody-detecting cassettes that use serum or a few drops of peripheral blood, rapid antigen tests on nasopharyngeal samples, and allin-one qRT-PCR platforms such as Cepheid's GeneXpert, which provides highly sensitive and specific results relative to the gold standard in a fraction of the time 10,11 . However, a key limitation is lack of scalability, with each (very expensive) machine only able to run one or a few samples at a time, with only a fixed number of single-source, single-use cassettes available per site per day. The intense demand for cartridges across all jurisdictions makes overall access limited. More recently, nucleic acid isothermal amplification (NAIA) techniques, including loopmediated isothermal amplification (LAMP), recombinase-polymerase amplification (RPA) and transcription-mediated amplification (TMA) have been shown to detect SARS-CoV-2 with very high sensitivity and specificity 12, 13 . Isothermal amplification underlies several tests recently authorized for emergency use, including the ID NOW from Abbott (recently approved in Canada) and CRISPR-based detection using SHERLOCK 14 (currently not approved for sale outside the United States). The ID NOW compares favourably to GeneXpert 15 , but also shares its disadvantages in terms of single sample per use and single-source cartridges. The LAMP/CRISPR test requires no special machines or cartridges, requiring only strip tubes or plates and p10 filter tips, hence it can easily be scaled up to conduct hundreds or thousands of tests. New England Biolabs' Colorimetric WarmStart LAMP kit can also be scaled and, thankfully, is available in Canada in various formulations. Incubation requires a simple heating block, or even a warm thermos that can hold the required temperature until DNA amplification is complete. Since DNA All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint amplification produces protons, the pH of the reaction drops and can conveniently be interpreted by eye using colour-sensitive pH stains, such as cresol red. In this study, we evaluated how a commercial colorimetric RT-LAMP kit combined with published SARS-CoV-2 primer sets and heat-treated, diluted sample compares with "gold standard" RT-PCR analysis conducted by our central laboratory. Archived sample set -A total of 101 leftover nasopharyngeal swab samples in viral transport medium, previously tested for SARS-CoV-2 by RT-PCR using E gene primers and purified RNA template on the Cobas or Panther Fusion platforms, were used to validate a recently described RT-LAMP assay. 50 samples were RT-PCR positive, with fluorescence threshold values between 10 and 37 cycles, and 51 samples were RT-PCR negative. Samples were de-identified and only RT-PCR and RT-LAMP results were retained for analysis. All study procedures were reviewed and approved by the Biomedical Research Ethics Board, University of Sample processing and heat treatment -After assigning blinded sample identifiers to reduce potential bias in interpretation, samples were thawed and briefly spun down in a minicentrifuge to collect cells and debris. An aliquot of 60 μl, drawn from the bottom of the tube near the pelleted material, was transferred to a 1.7 ml Eppendorf tube, labelled with the blinded code, then incubated in a heating block at 95˚C for 5 minutes. Serial tenfold dilutions of sample were prepared in nuclease-free water (New England Biolabs, Whitby, ON). WarmStart LAMP Kit (New England Biolabs) and a published LAMP primer set targeting the N All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. Sensitivity, specificity and predictive values -Sensitivity of the RT-LAMP assay using raw, heat-inactivated sample was 77% compared to RT-PCR of purified RNA extracts (Table 1) . Samples with the lowest Ct values (<22) were all bright yellow by RT-LAMP, even when diluted up to 1000-fold, indicating a similar range of detectable concentration to the positive control. All RT-PCR negatives were also RT-LAMP negative (Table 1 ). This indicates that RT-All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint RT-LAMP vs. RT-PCR -Manuscript 6 LAMP may be most useful to more quickly detect those with high viral loads in their specimen who are most likely to transmit the virus to others. Accuracy 85% (76-91%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint Interpretation of colour change -Only samples that were bright yellow after 30 minutes incubation were considered positive (Figure 1 ). In some cases, a partial colour change resulted, from magenta to pink to orange, but did not become yellow within the period of observation in which the positive control always turns yellow (20-30 minutes, regardless of dilution factor down to 1,000 copies). This partial colour change may indicate a weak positive (all samples do eventually turn yellow), a failed reaction (not indicating anything about the sample itself), or a true negative, depending on the reason for the weak change in pH. Pink and orange reactions were also more frequent when undiluted raw sample or 10% v/v template/reaction mixture was used. Interpretation of colour in tests on Samples 9-24 -Only bright yellow results after 30 minutes at 65˚C are considered positive. Magenta colour indicates a "true" negative (insufficient viral RNA), while orangey colour is considered "indeterminate" and re-tested. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint Controls and limit of detection -Negative controls were reliably magenta throughout the experiments ( Figure 2 ) but did eventually get contaminated. Routine cleanup with DNAse and careful separation of pre-amplification and amplification/post-amplification areas are required (unless you use NEB's more expensive dUTP kit) to prevent the massive DNA contamination that LAMP is prone to. The MERS DNA negative control at 1,000 and 10,000 copies did not produce any yellow colour, however 100,000 copies resulted in a positive reaction (not shown). SARS-CoV-2-N DNA positive control produced a bright yellow reaction within 30 minutes down to 1,000 copies, but remained magenta at lower dilutions, indicating 10 3 viral copies per μl as the lower limit of detection for the current conditions ( Figure 2 ). No template control (NTC). In this study, we confirm that one of the fastest, simplest, cheapest and most scalable protocols available for detecting SARS-CoV-2 nucleic acid is so far reliable for strong positives only, but highly specific compared to "gold standard" qRT-PCR detection. Other studies have All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint shown similar reduced sensitivity but high specificity 17-21 . One early study found that RT-LAMP was more sensitive than RT-PCR at detecting virus in an asymptomatic carrier monitored for several days 22 . RT-LAMP has been tested extensively at large scale in the UK and has recently been shown to have less-than-expected sensitivity (<50%) when rolled out to large populations as part of Operation Moonshot 23 . However, similarly to the current study, sensitivity was greatest in strong positives, indicating that only those with high viral loads may reliably be detected with this diagnostic platform, especially when performed by non-experts in field settings. The pace of Canadian approvals for SARS-CoV-2 point-of-care diagnostic tests has been much faster than for other infections over the years (such as HIV/STBBI). Initial conditional approvals were revoked for the isothermal amplification-based Spartan Cube and its apparently inadequate silicon sampling devices. Recent approvals have included a rapid isothermal platform (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint jurisdictions are exploring use of PanBio Ag Rapid Test Device to identify positives early, assuming that negative results will need additional testing in order to be confirmed 26-28 . Molecular diagnostic techniques that use raw or minimally processed sample are fastest, but less sensitive, since the background chemistry of a raw sample may introduce uncontrolled variability 18, 29 . Potential inhibitors or other contaminants may reduce the reliability of both positive and negative results. This concern is somewhat lessened in the context of the current report, which we have confirmed is highly specific and can amplify target molecules even in highly diluted samples. However, the current assay's limit of detection (currently 1,000 copies/μl, similar to other studies 18 ) does decrease the likelihood of detecting a person with low viral load. In contrast, Sherlock Biosciences claims on its website (www.sherlock.bio) that its LAMP-based assay can detect 7 copies per μl VTM or up to 150 times less than this report. Is the risk of missing someone with a low viral load greater than making a person with a high viral load wait days to find out they are positive? In all cases, expectations about what a negative test result actually means must be properly managed. In this study, RT-LAMP with raw, heat-treated sample was ~75% sensitive compared to nasopharyngeal RT-PCR ("the gold standard"), meaning that a false negative result can be expected 1 out of 4 times the test is performed. Therefore, careful explanation that a single negative test does not mean a person is free of SARS-CoV-2 must be included as part of pre-test and post-test counselling. However, RT-LAMP using raw sample is much cheaper and faster than RT-PCR using purified RNA (Table 2) . Multiple RT-LAMP tests can be conducted in less time and at less cost than a single "gold standard" RT-PCR test. Repeat screening over several days may also help identify the earliest timepoint at which a person is infectious, increasing confidence that a All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint negative test result is not just due to random error or low test sensitivity 30 , and increasing the impact of contact tracing. All consumables, equipment and hours worked were donated. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR Genomic characterization of the 2019 novel humanpathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan Serology-based and molecular-based tests tracker. Bloomberg School of Public Health COVID-19 In Vitro Diagnostic Devices and Test Methods Database. 2020 Coronavirus Test Tracker: Commercially Available COVID-19 Diagnostic Tests. 360Dx.com; 2020 Reporting of sexually transmitted infections during the COVID-19 pandemic Put an end to asymptomatic testing, before the system gets overwhelmed. National Post Why Only Test Symptomatic Patients? Consider Random Screening for COVID-19. Appl Health Econ Health Policy No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Comparison of the NeuMoDX, Diasorin Simplexa, Cepheid and Roche CDC SARS-CoV EUA assays using nasopharyngeal/nasal swabs in universal transport media (UTM) and sputum and tracheal aspirates Clinical Evaluation of Three Sample-To-Answer Platforms for the Detection of SARS-CoV-2 Detection of SARS-CoV-2 using non-commercial RT-LAMP reagents and raw samples Sensitive, Specific, and Cost-Effective Point-of-Care Test for Coronaviruses in the Context of COVID-19 Pandemic Point-of-care testing for COVID-19 using SHERLOCK diagnostics Comparison of Cepheid Xpert Xpress and Abbott ID Now to Roche cobas for the Rapid Detection of SARS-CoV-2 Rapid Molecular Detection of SARS-CoV-2 (COVID-19) Virus RNA Using Colorimetric LAMP. medRxiv No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted Optimizing direct RT-LAMP to detect transmissible SARS-CoV-2 from primary patient samples A Rapid, Simple, Inexpensive, and Mobile Colorimetric Assay COVID-19-LAMP for Mass On-Site Screening of COVID-19 Rapid detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform Detecting SARS-CoV-2 at point of care: preliminary data comparing loop-mediated isothermal amplification (LAMP) to polymerase chain reaction (PCR) Development and Clinical Application of a Rapid and Sensitive Loop-Mediated Isothermal Amplification Test for SARS-CoV-2 Rapid test missed over 50% of positive cases in Manchester pilot Lucira Health's At-Home Covid Test, Explained COVID-19 Diagnostics: How Do Saliva Tests Compare to Swabs? The Scientist Field evaluation of a rapid antigen test (Panbio COVID-19 Ag Rapid Test Device) for COVID-19 diagnosis in primary healthcare centers Evaluation of the PanbioTM rapid antigen test for SARS-CoV-2 in primary health care centers and test sites Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms Rapid SARS-CoV-2 testing in primary material based on a novel multiplex LAMP assay Test, re-test, re-test': using inaccurate tests to greatly increase the accuracy of COVID-19 testing Combined Point-of-Care Nucleic Acid and Antibody Testing for SARS-CoV-2 following Emergence of D614G Spike Variant All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint All rights reserved. No reuse allowed without permission.(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.The copyright holder for this preprint this version posted December 8, 2020. ; https://doi.org/10.1101/2020.12.07.20239558 doi: medRxiv preprint